(lp0
S"Aradigm Corp.  Announces Mixed Results from Two Pulmaquin Phase 3s in ... StreetInsider.com - Dec 1, 2016 Aradigm Corporation  announced top-line results from its two Phase 3 clinical trials  evaluating the safety and efficacy of Pulmaquin, the Company's investigational proprietary formulation of once daily ciprofloxacin ..."
p1
aS'1.81 MarketWatch - Apr 21, 2011 22, 2016 at 4:15 p.m. ET; on InvestorPlace.com. 3 Reasons Why Aradigm Corporation  is a Great Momentum Stock. Sep. 22, 2016 at 9:11 a.m.'
p2
aS'6 Reasons Aradigm Corporation Is An Excellent Risk Vs. Reward Opportunity Seeking Alpha  - Aug 8, 2014 Yet, we managed to discover an intriguing biotech small cap with an excellent risk vs. reward profile called Aradigm Corporation . This company possesses exactly the right features that made us aggressively buy shares in the open market:.'
p3
aS"3 Reasons Why Aradigm Corporation  is a Great Momentum Stock September ... Zacks.com - Sep 22, 2016 This method discovered several great candidates for momentum-oriented investors, but today let's focus in on Aradigm Corporation as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be ..."
p4
aS"Don't Write Off Aradigm Corporation  Just Yet Market Exclusive - Dec 2, 2016 A number of small cap biotech companies took a hit on their market capitalization on Thursday, but none more sharply than Aradigm Corporation . The company put out some data relating to its lead investigational asset, Pulmaquin, and&nbsp;...Pulmaquin failure halves Aradigm's value - The Pharma Letter "
p5
aS"Notable Wall Street Stock: Aradigm Corporation's  stock price finalizes ... WsNews 4investors - Mar 17, 2017 Aradigm Corporation  stock price distance from twenty day simple moving average slumped at -6.10% while its distance from fifty day simple moving average declined -4.77% along with -53.86% below distance from two hundred simple moving&nbsp;..."
p6
aS'Aradigm Announces Completion of Patient Enrollment for Second Phase III Study ... Lung Disease News - Oct 14, 2015 Aradigm Corporation, a pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases, recently announced the conclusion of patient enrollment in the ORBIT-3 trial, the&nbsp;...'
p7
aS'Grifols, SA and Aradigm Corporation Announce Signing of Worldwide Licensing ... Business Wire  - May 21, 2013 BARCELONA, Spain &amp; HAYWARD, Calif.----Grifols, S.A.   and Aradigm Corporation   today announced the signing of an exclusive, worldwide license&nbsp;...'
p8
aS"Noteworthy Stock: Aradigm Corporation's  stock price ends at $1.85 with ... WsNews 4investors - Mar 16, 2017 Aradigm Corporation  stock price distance from twenty day simple moving average slumped at -4.59% while its distance from fifty day simple moving average declined -2.41% along with -52.99% below distance from two hundred simple moving&nbsp;..."
p9
aS"Aradigm Announces Decision for Centralized Review of Pulmaquin by the European ... Business Wire  - Mar 17, 2016 HAYWARD, Calif.----Aradigm Corporation   today announced that the European Medicines Agency  has approved its request to review Pulmaquin, Aradigm's investigational inhaled liposomal&nbsp;..."
p10
a.